Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dehydrodolichyl diphosphate synthase subunit (DHDDS) is a highly conserved enzyme and the catalytic core of the human cis-prenyltransferase complex. DHDDS catalyzes cis-prenyl chain elongation by joining isopentenyl diphosphate and farnesyl diphosphate, producing the polyisoprenoid backbone of dolichol, a lipid essential for protein N-glycosylation in the ER. The enzymatic activity and substrate specificity require heteromerization with the Nogo-B receptor (NgBR). DHDDS mutations disrupt dolichol synthesis and are causally associated with diseases like autosomal recessive retinitis pigmentosa and developmental epileptic encephalopathies, emphasizing its central role in human metabolism and disease.
not applicable (no approved drugs); theoretical mechanism would be enzyme inhibition, blocking dolichol synthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dehydrodolichyl diphosphate synthase subunit (DHDDS).